Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.

Marco Di BattistaLaura TavantiFrancesco PistelliLaura CarrozziMattia Da RioAlessandra RossiLorenzo PuccettiAntonio TavoniChiara RomeiRiccardo MorgantiAlessandra Della RossaMarta Mosca

Published in: Inflammopharmacology (2023)

We presented data on the NIN safety profile in a real life setting, which was similar between SSc-ILD and IPF. A combination of multiple managing strategies and dose adjustment appears essential to cope optimally with NIN adverse effects.

Keyphrases

interstitial lung disease
idiopathic pulmonary fibrosis
systemic sclerosis
electronic health record
big data
rheumatoid arthritis
machine learning